| [1］ Sand PK, Koduri S, Lobel RW, et al. Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles［J］. Am J Obstet Gynecol,2001,184(7): 1357-1364. [2］ Nieminen K, Hiltunen R, Takala T, et al. Outcomes after anterior vaginal wall repair with mesh: a randomized, controlled trial with a 3 year follow-up［J］. Am J Obstet Gynecol,2010,203(3): 235 e1-8. [3］ Altman D, Vyrynen T, Engh ME, et al. Nordic transvaginal mesh group:anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse［J］. N Engl J Med,2011,364(19):1826-1836. [4］ Maher C, Feiner B, Baessler K,et al. Surgical management of pelvic organ prolapse in women［J］. Cochrane Database Syst Rev,2010,14(4):CD004014.1 [5］ Food and Drug Administration. FDA safety communication: UPDATE on serious complications associated with transvaginal placement of surgical mesh for pelvic organ prolapse［J］. Silver Spring (MD): FDA, 2011. Available at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm. July 27, 2011. [6］ Committee on Gynecologic Practice.Vaginal placement of synthetic mesh for pelvic organ prolapse［J］. Female Pelvic Med Reconstr Surg, 2012,18(1):5-9. [7］ American Urogynecologic Society's Guidelines Development Committee.Guidelines for providing privileges and credentials to physicians for transvaginal placement of surgical mesh for pelvic organ prolapse［J］.Female Pelvic Med Reconstr Surg, 2012,18(4):194-197. [8］ Stanford E, Moen M. Patient safety communication from the Food and Drug Administration regarding transvaginal mesh for pelvic organ prolapse surgery［J］. J Minim Invasive Gynecol,2011,18(6):689-691. [9］ Murphy M, Holzberg A, van Raalte H,et al. Time to rethink: an evidence-based response from pelvic surgeons to the FDA Safety Communication: "UPDATE on Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse"［J］.Int Urogynecol J,2012,23(1):5-9. |
